

**CLAREON® PANOPTIX® HAS A CLINICALLY PROVEN AND PREDICTABLE CONTINUOUS RANGE OF VISION<sup>1†\*\*</sup>**


**Can RayOne\* Galaxy\* deliver the same full range of vision?**



AcrySof® IQ PanOptix®  
Trifocal Intraocular Lens  
Alcon

**Clareon® PanOptix® shows superior MTF bench performance at near and intermediate<sup>††2</sup>**


**MTF image quality at 3mm aperture<sup>†</sup>**



**5x** More MTF image quality at near with PanOptix® (based on bench data with 50 lp/mm = 20/40 Snellen)<sup>†2</sup>


**PanOptix® can achieve 20/20 at distance, intermediate and near, with 20/25 or better in the very near at 33cm<sup>†,§§,3</sup>**

**Mean binocular clinical defocus curve at 3-6 months<sup>†,§§,1</sup> (n=542)**




**Clareon® PanOptix® demonstrates high axial stability and predictable long-term refractive outcomes<sup>1,4</sup>**

**Axial Displacement (posterior) for Clareon® PanOptix® and RayOne\* (9mm)<sup>†</sup>**



**9 mm Compression<sup>4</sup>**



Clareon® PanOptix®

RayOne\* EMV monofocal<sup>§</sup>


● Clareon® PanOptix® ● RayOne\* p > 0.05 compared to RayOne\*. SD = Standard Deviation. Individual standard deviations are used to calculate the intervals.

Alcon medical device(s) comply with the current legislation for the medical devices. Please refer to relevant products instructions for use for complete list of indications, contraindications and warnings.

1. Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical Outcomes After Bilateral Implantation of a Directive Trifocal Intraocular Lens: A Worldwide Pooled Analysis of Prospective Clinical Investigations. Clin Ophthalmol. 2023;17:155-163. 2. Alcon Data on File, REF-26875, 2025. 3. Grzybowski A, Zernatienė R, Markevičiūtė A, Tuuminen R. Should We Abandon Hydrophilic Intraocular Lenses? AJO, 2022 (237): 139-145. 4. Alcon Data on File, REF-238077, 2024. 5. https://www.gatinel.com/spiral-optics-presentation-and-explanations/. 6. Zhu D, Zhang J, et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston. 7. Zhu D, Ren S, Mills K, Hull J, Dhariwal M. Rate of Complete Spectacle Independence with a Trifocal Intraocular Lens: A Systematic Literature Review and Meta-Analysis. Ophthalmol Ther. 2023;12(2):1157-1171. 8. Market Scope IOL Report 2024. 9. Modi et al. Visual and Patient-Reported Outcomes of a Directive Trifocal Intraocular Lens Compared with Those of a Monofocal Intraocular Lens. 2020 Sep 28;S0161-6420(20)30677-1.

# Similar optical bench halo profile between PanOptix® and Galaxy\*2



## Halo Area Under the Curve (AUC)<sup>†2</sup>



Galaxy\* only shows 3.4% less halo profile vs PanOptix®<sup>†2</sup>

## WILL THIS VORTEX GEOMETRY IMPACT VISUAL QUALITY?

“As a consequence of this particular vortex geometry, the convolution of images for focal points outside the focal zone shows « ghost » replicas, which are linked to the particular grouping of certain ray bundles.”<sup>5</sup>



## CLAREON® PANOPTIX® DELIVERS

CLINICALLY PROVEN LOW LEVELS OF BOTHERSOME VISUAL DISTURBANCES<sup>6†</sup>


**97%**  
(n=580)

of patients reported **no “very bothersome”** visual disturbances

## PANOPTIX® PROVIDES VERY HIGH LEVELS OF SPECTACLE INDEPENDENCE WITH OUTSTANDING PATIENT SATISFACTION

More than **9 out of 10** PanOptix® IOL patients reported **NEVER** needing glasses at all distances<sup>†7</sup>

PanOptix® is the world’s leading trifocal IOL and has been implanted over 3 million times<sup>Δ8</sup>



**96%**  
at Distance Vision<sup>7</sup>



**96%**  
at Intermediate Vision<sup>7</sup>



**90%**  
at Near Vision<sup>7</sup>

**99.2%**  
OF PANOPTIX® PATIENTS WOULD HAVE THE SAME LENS IMPLANTED AGAIN (N=127)<sup>†#9</sup>

Local Alcon customer service & sales reps

Local Alcon clinical support

Regional & online training resources

ISO-certified manufacturing plants for highest environmental & quality standards

\*Trademarks are the property of their respective owners. \*\*Pooled mean binocular defocus curve at 3-6mo post op from 6 prospective trials on AcrySof® IQ PanOptix® in cataract patients. †Based on data for AcrySof® IQ PanOptix® Trifocal IOL. AcrySof® IQ PanOptix® is optically equivalent to Clareon® PanOptix®. ††Based on Modular Transfer Function at 50 lp/mm (≈20/40 LogMAR) and 100 lp/mm (≈20/20 LogMAR). †Based on bench data. ††Snellen VA was converted from logMAR VA. A Snellen notation of 20/20-2 or better indicates a logMAR VA of 0.04 or better, which means 3 or more of the 5 Early Treatment Diabetic Retinopathy Study chart letters in the line were identified correctly. †RayOne Galaxy is based on the same platform as RayOne EMV. †Based on optical bench data. †Based on a meta-analysis of 13 studies with a total of more than 600 patients. †Based on global Clareon® PanOptix® and AcrySof® PanOptix® unit sales until 2024. †n=127; Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op: “Given your vision today, if you had to do it all over, would you have the same lenses implanted again?”.